Fermenta Biotech Ltd · BSE:FERMENTA
Fermenta Biotech — Q4 FY2025 Earnings Presentation
17 slides from Fermenta Biotech's earnings presentation, Jun 4, 2025
Slide 1: Intimation of Investor Presentation to BSE
Fermenta Biotech Limited CIN: L99999MH1951PLC008485 Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India. Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com Ref: F.No.: 908 June 4, 2025 Corporate
Slide 2: Fermenta Biotech Ltd Q4/FY25 presentation
Fermenta Biotech Ltd Q4/FY25 presentation 4 June 2025
Slide 3: Disclaimer
Disclaimer By viewing this presentation, the recipient agrees that neither Fermenta Biotech Limited (“FBL”) nor any of its affiliates, directors, officers, employees, or representatives shall be liable for any loss, damage, or liability arising directly or indirectly from the use of or reliance on t
Slide 4: Best-in-class nutritional ingredients provider
Fermenta provides best-in-class, scientifically-validated nutritional ingredients for the world’s leading brands in the pharmaceutical, dietary supplement, food and beverage, and veterinary and animal feed industries. Our edge? Decades of expertise in global-scale, high-value manufacturing, and rese
Slide 5: Q4/FY25 Highlights
Q4/FY25 Highlights Financials (consolidated) with Real Estate Performance Q4FY25 FY25 Human nutrition volume grew by 48% over FY24. ₹ 143.7 crore Animal nutrition volume grew by 24% over FY24. ₹ 481.3 crore Revenue (up 40% YoY, down (up 39% YoY) The company successfully completed validation batches
Slide 6: Consolidated Key Financials
Consolidated Key Financials Strong Recovery with Debt Reduction & Operational Efficiency (₹ Crore) (₹ Crore) 469 350 43 116 105 41 Revenue 399 Cash flow from operations 377 40 336 193 236 210 70 122 Gross Fixed Assets 205 90 154 EBITDA 39 26 217 229 236 132 Gross Debt 109 76 15 43 PAT 58 45 72 (53)
Slide 7: Lines of Business
Lines of Business Nutrition Primary revenue source focused on nutritional ingredients for health and wellness industries Vitamin D3 - Human Vitamin D3 - Animal Others Premium supplements, food Specialized formulations for Vitamin D analogs and specialized fortification, and pharmaceuticals livestock
Slide 8: Revenue Mix (Consolidated)
Revenue Mix (Consolidated) (₹ Crore) FY22 FY23 FY24 FY25 Nutrition Business 350 248 217 350 6% 13% 18% 9% 8% 4% Vitamin D3 - Human Nutrition 224 163 141 216 Others 12 % 6% 6% 14% Vitamin D3 - Animal Nutrition 79 37 38 94 11% 8% D3 – Animal Others 47 48 39 40 13% 19 % 14% Other Business 33 40 46 67 1
Slide 9: Performance Ratios (Consolidated)
Performance Ratios (Consolidated) Higher Profitability | Stronger Balance Sheet FY 22 FY 23 FY 24 FY 25 FY25 showed strong recovery: Liquidity EBITDA margin hit 26%, ROE rose Current 1.5 1.2 1.4 1.52 23%, debt ratios improved, and Quick 0.6 0.5 0.8 0.87 liquidity strengthened—signaling operational t
Slide 10: Key Balance Sheet Items
Key Balance Sheet Items Growth with Financial Agility (₹ Crore) FY25 FY24 % Change Comments Our disciplined financial stewardship Assets cut debt while expanding critical Total Assets 614 548 12% - assets–fueling future-ready growth Fixed Assets (Net) 226 238 -5% - without overleveraging Current Ass
Slide 11: Cash Flow
Cash Flow (₹ Crore) Particular FY25 FY24 Comments Operating Cash Flow Net Profit 83 (10) - Prudent working capital deployment Depreciation 24 25 - Working Capital Changes (83) 33 Increase in Inventory & Trade Receivables and debt reduction position us for Other Adjustments 16 58 - scalable growth Op
Slide 12: Cost Breakdown (% of Revenue) w/o Real Estate
Cost Breakdown (% of Revenue)—w/o Real Estate Optimization Drives Margin Expansion & Operational Efficiency Cost Components FY25 FY24 Change Key Drivers Raw Materials 35% 50% -14% Revenue mix Revenue increase offset Employee Cost 15% 22% -7% wage increases Increase in scale of Manufacturing Expenses
Slide 13: Revenue Growth Drivers
Revenue Growth Drivers Glocal Expansion | Strategic Pricing Driver Impact (₹ Cr) Impact % Volume Growth 85 33% Price Realization 68 22% New Products 2 61% International Markets 108 38% Domestic Growth 45 34% Successful penetration in new regions We scaled profitably across borders Strong demand sign
Slide 14: Globally Diversified Revenue with Balanced Customer Base
Globally Diversified Revenue with Balanced Customer Base Resilient Revenue Streams Geographical Revenue Mix Excl. Value Unlocking % of revenue from largest customer 9% % of revenue from top 5 customers 25% FY22 35% 25% 14% 26% % of revenue from top 10 customers 38% FY23 39% 21% 15% 24% % of revenues
Slide 15: The Opportunity
The Opportunity Leverage Fermenta’s strengths towards meeting evolving consumer needs and regulatory requirements across diverse markets India Global Innovation Drivers ✓ Preventive health awareness ✓ Nutritional supplements ✓ Nutrigenomics ✓ Growing middle class ✓ Aging drives vitamin D ✓ Natural/o
Slide 16: Fermenta's Value Proposition
Fermenta’s Value Proposition Society Contribute to global health and preventive care through nutritional ingredients Support life productivity across human and animal populations Address environmental challenges with custom and green chemistry solutions Best-in-class, science-backed Market leadershi
Slide 17: Thank you
Thank you Sumesh Gandhi - CFO sumesh.gandhi@fermentabiotech.com Fermenta Biotech Ltd